Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 2/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248605 | 1.00 | CA9 (0.69) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL5450511 | 0.96 | CA9 (0.75) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL4253079 | 0.92 | PTGES (0.70) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL3956749 | 0.92 | PTGES (0.70) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL8230670 | 0.92 | PTGES (0.70) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL13855629 | 0.91 | CA9 (0.71) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL14374364 | 0.91 | CA9 (0.61) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL5449653 | 0.91 | PTPN1 (0.71) | CA9SLC10A1CA1CA2PTPN1 | |
| SCHEMBL25816686 | 0.90 | CA9 (0.69) | CA9SLC10A1PRKCDCA1CA2 | |
| SCHEMBL25815828 | 0.90 | CA9 (0.69) | CA9SLC10A1PRKCDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | EBP, PGGT1B, LIPC | CA9 3407/4885SLC10A1 1248/4885PRKCD 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.